PEER - Evidence Summaries - Guidelines

PRACTICAL EVIDENCE FOR INFORMED PRACTICE CONFERENCE

See some of the sights of another great PEIP Conference. We thought it was great but don’t take our word for it read the post conference evaluations from our attendees. If you would like to attend other great PEER events sign up for the PEER Newsletter. Also, stay alerted to all PEER news and be the first to get the scoop on our 2023 PEIP Conference, October 20-21, 2023!

CFPCLearn’s primary care focused library includes a variety of content including evidence summaries, videos, podcasts and interactive learning courses to support clinicians in their practice.

Most Recent Tools for Practice

Tools for Practice #341 Forget about it? Statins and the risk of dementia

Do statins negatively affect cognition, memory, or dementia?

Randomized controlled trials (RCTs) and large, long-term observational studies suggest no association between statins and risk of dementia or worsening cognition scores. Read More

29 May 2023

Tools for Practice #340 – Crying babies: Can proton pump inhibitors help?

In infants (≤1year) with crying/irritability attributed to feeds, do proton pump inhibitors (PPIs) improve symptoms over placebo without additional harms?

PPIs do not improve crying, fussiness, irritability, or regurgitation attributed to feeds. However, PPIs may increase the risk of serious adverse effects (e.g., respiratory tract infections) from 2.5% on placebo to 12% at 4 weeks. Read More

15 May 2023

Tools for Practice #339 Is acetaminophen under pressure?

Does regular use of acetaminophen increase blood pressure?

Taking 3-4g of acetaminophen per day for 2-4 weeks increases systolic blood pressure by 3-4 mmHg. Clinicians should consider that regular use of acetaminophen can be a cause of elevated blood pressure in some patients. Read More

1 May 2023

Tools for Practice #338 Ritonavir-boosted nirmatrelvir (Paxlovid®): And you thought we were done with COVID! (Free)

Is ritonavir-boosted nirmatrelvir (Paxlovid®) a safe and effective oral therapy for the treatment of COVID-19?

In unvaccinated patients at risk of severe outcomes, oral ritonavir-boosted nirmatrelvir (Paxlovid^®) reduces the risk of hospitalization due to COVID-19 from 6.2% to 0.8% and all-cause mortality from 1.2% to 0%. Real-world evidence suggests effectiveness in Omicron-infected. Adverse events include taste disturbances and potentially serious drug interactions exist. Read More

17 April 2023

Tools for Practice #337 – Clear, not cloudy: Antibiotic options for uncomplicated urinary tract infections

What is the preferred treatment regimen for uncomplicated Urinary Tract Infections (UTI)?

For symptom resolution, all antibiotics are similar. Based on limited evidence, best guidance for treatment durations for symptom resolution are nitrofurantoin 5-day; trimethoprim-sulfamethoxazole, beta-lactams, ciprofloxacin and norfloxacin 3-day, and fosfomycin 1-day. Treatment choice should be driven by patient preference, local resistance, side effects, and allergies. Read More

3 April 2023

PEER Values

When creating primary care education and programs, the PEER team focuses on minimizing bias, patient orientated outcomes, shared decision making, collaboration and most importantly simplicity.

Who is PEER?

Patients, Experience, Evidence and Research (PEER) was formed between a group of primary care providers who shared a common belief that evidence should be made accessible to all primary care providers.

Empowering Primary Care Through Evidence

An impossible job, done impossibly well